A Study to Assess a PI3Kδ Inhibitor (IOA-244) in Patients With Metastatic Cancers
iOnctura
iOnctura
Ipsen
Ipsen
Taproot Health
Ascentage Pharma Group Inc.
Eli Lilly and Company
Incyte Corporation
Curis, Inc.
National Institutes of Health Clinical Center (CC)
Shenzhen BinDeBio Ltd.
Mayo Clinic
Novartis
Stanford University
Novartis
Stanford University
Valerio Therapeutics
University of Chicago